InnoCare Pharma Limited (HKG:9969)

Market Cap	28.30B
Revenue (ttm)	1.45B
Net Income (ttm)	-228.89M
Shares Out	1.76B
EPS (ttm)	-0.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,361,000
Average Volume	15,560,245
Open	14.38
Previous Close	14.26
Day's Range	13.74 - 14.38
52-Week Range	5.02 - 20.62
Beta	0.93
RSI	34.91
Earnings Date	Nov 14, 2025

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 939
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9969

Financial Performance

In 2024, InnoCare Pharma's revenue was 1.01 billion, an increase of 36.68% compared to the previous year's 738.54 million. Losses were -440.63 million, -30.20% less than in 2023.

Financial numbers in CNY